Home > Insider Trading > Filing (0001209191-21-058123)

Filing Details

Accession Number:: 0001209191-21-058123
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-29 19:16:33
Reporting Period:: 2021-09-27

Accepted Time:: 2021-09-29 19:16:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1733294	Generation Bio Co.	GBIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1577014	P Jason Rhodes	C/O Generation Bio Co. 301 Binney Street Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-27	51,294	$25.70	29,645	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-27	95	$25.70	662	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-28	13,089	$25.24	16,556	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-28	24	$25.24	638	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-29	16,556	$24.59	0	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-29	30	$24.59	608	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,111,939	Indirect	See footnote
Common Stock	1,166,937	Indirect	See footnote

Footnotes

Shares were sold pursuant to a Rule 10b5-1 trading plan dated April 20, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.15 to $26.07 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6).
The shares are held directly by Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of such securities held by AVA X LP, except to the extent of his pecuniary interest therein, if any.
The shares are held directly by Atlas Venture Associates Opportunity I, LP ("AVAO LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVAO LP, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.93 to $25.79 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.46 to $25.36 inclusive.
These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is AVA X LP. AVA X LLC is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend if its pecuniary interest therein, if any.
The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). AVAO LP is the general partner of AVOF I. AVAO LLC is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.